دورية أكاديمية
Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs.
| العنوان: | Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. |
|---|---|
| المؤلفون: | Leeneman B; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA Rotterdam, The Netherlands., Uyl-de Groot CA; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA Rotterdam, The Netherlands.; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA Rotterdam, The Netherlands., Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center+, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands., van Akkooi ACJ; Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Center, Dr. H. van der Hoffplein 1, 6162 BG Sittard-Geleen, The Netherlands., van den Eertwegh AJM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1118, 1182 DB Amsterdam, The Netherlands., de Groot JWB; Oncology Center Isala, Isala, Dokter van Heesweg 2, 8025 AB Zwolle, The Netherlands., Herbschleb KH; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands., van der Hoeven JJM; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands., Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands., Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, The Netherlands., van Rijn RS; Department of Internal Medicine, Medical Center Leeuwarden, Henri Dunantweg 2, 8934 AD Leeuwarden, The Netherlands., Suijkerbuijk KPM; Department of Medical Oncology, UMC Utrecht Cancer Center, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Ten Tije AJ; Department of Internal Medicine, Amphia Hospital, Molengracht 21, 4818 CK Breda, The Netherlands., van der Veldt AAM; Department of Medical Oncology, Erasmus MC Cancer Institute, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands., Vreugdenhil G; Department of Internal Medicine, Maxima MC, Dominee Theodor Fliednerstraat 1, 5631 BM Eindhoven, The Netherlands., Wouters MWJM; Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands., Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands., Franken MG; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA Rotterdam, The Netherlands.; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA Rotterdam, The Netherlands. |
| المصدر: | Cancers [Cancers (Basel)] 2020 Apr 18; Vol. 12 (4). Date of Electronic Publication: 2020 Apr 18. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
| مستخلص: | Immunotherapeutic and targeted drugs improved survival of patients with metastatic melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice. The aim of our study was to provide insight into real-world healthcare costs of patients with metastatic cutaneous melanoma. Data were obtained from the Dutch Melanoma Treatment Registry for patients who were registered between July 2012 and December 2018. Mean total/monthly costs per patient were reported for all patients, patients who did not receive systemic therapy, and patients who received systemic therapy. Furthermore, mean episode/monthly costs per line of therapy and drug were reported for patients who received systemic therapy. Mean total/monthly costs were € 89,240/€ 6809: € 7988/€ 2483 for patients who did not receive systemic therapy ( n = 784) and € 105,078/€ 7652 for patients who received systemic therapy ( n = 4022). Mean episode/monthly costs were the highest for nivolumab plus ipilimumab (€ 79,675/€ 16,976), ipilimumab monotherapy (€ 79,110/€ 17,252), and dabrafenib plus trametinib (€ 77,053/€ 12,015). Dacarbazine yielded the lowest mean episode/monthly costs (€ 6564/€ 2027). Our study showed that immunotherapeutic and targeted drugs had a large impact on real-world healthcare costs. As new drugs continue entering the treatment landscape for (metastatic) melanoma, it remains crucial to monitor whether the benefits of these drugs outweigh their costs. |
| References: | Eur J Cancer. 2017 Feb;72:156-165. (PMID: 28030784) Anticancer Drugs. 2018 Jul;29(6):579-588. (PMID: 29634490) Eur J Cancer. 2019 Dec;123:58-71. (PMID: 31670077) Melanoma Res. 2015 Aug;25(4):312-20. (PMID: 25882026) J Clin Oncol. 2000 Nov 15;18(22):3782-93. (PMID: 11078491) Curr Med Res Opin. 2015 Aug;31(8):1561-72. (PMID: 26086578) PLoS One. 2017 Nov 9;12(11):e0187477. (PMID: 29121647) J Am Coll Surg. 1995 Sep;181(3):193-201. (PMID: 7670677) Drugs Context. 2012 Nov 19;2012:212242. (PMID: 24432031) Ned Tijdschr Geneeskd. 2018 Jun 15;162:. (PMID: 30040270) |
| فهرسة مساهمة: | Keywords: healthcare costs; immunotherapy; metastatic melanoma; real-world data; targeted therapy |
| تواريخ الأحداث: | Date Created: 20200425 Latest Revision: 20200928 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC7225943 |
| DOI: | 10.3390/cancers12041003 |
| PMID: | 32325748 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!